Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma
2012 (English)In: Medical Oncology, ISSN 1357-0560, E-ISSN 1559-131X, Vol. 29, no 1, 301-303 p.Article in journal (Refereed) Published
Poorly differentiated endocrine carcinomas (PDEC) are usually treated with cisplatin-based chemotherapy regimens. We here present a case with a dramatic response (both radiologically and biochemically) to the combination of temozolomide and bevacizumab, after failure of cisplatin and etoposide, with continued tumor shrinkage at 5 months. Temozolomide combined with bevacizumab might be a good treatment option in PDEC, perhaps even in a first-line setting. Prospective studies to answer this are warranted.
Place, publisher, year, edition, pages
2012. Vol. 29, no 1, 301-303 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-149251DOI: 10.1007/s12032-010-9789-4ISI: 000300317200046PubMedID: 21191667OAI: oai:DiVA.org:uu-149251DiVA: diva2:404245